Skip to content
OpenCapital
Get started

Bioventus BVS Restorative Therapies — Total Net Sales

Other product segments

Pain Treatments
$63.43M+7.7%
Surgical Solutions
$48.03M+6.2%

Similar metrics at other companies

Amneal Pharmaceuticals, Inc. logo
AMRXSubtotal therapeutic classes — Net revenue
$133.27M+23.1%
Enovis logo
ENOVReconstructive — Net Sales
$317.13M+10.8%
Baxter International logo
BAXMedical Products & Therapies — Net Sales
$1.29B+1.8%
Avanos Medical logo
AVNSTotal Pain Management and Recovery — Net Sales
$56.3M+0.2%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×—
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%—
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's restorative therapies — total net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's restorative therapies — total net sales?
Bioventus (BVS) reported restorative therapies — total net sales of $20.64M in Q1 2026.
How has Bioventus's restorative therapies — total net sales changed year-over-year?
Bioventus's restorative therapies — total net sales increased by 4.6% year-over-year, from $19.72M to $20.64M.
What is the long-term trend for Bioventus's restorative therapies — total net sales?
Over 4 years (2021 to 2025), Bioventus's restorative therapies — total net sales has grown at a -8.5% compound annual growth rate (CAGR), from $121.57M to $85.37M.
What does restorative therapies — total net sales mean?
This metric represents the total revenue generated from the sale of products and services within the restorative therapies business unit, net of returns, allowances, and discounts. It serves as a primary indicator of market demand and the commercial success of the company's regenerative medicine and orthopedic healing portfolio. Tracking this figure helps investors assess the growth trajectory and competitive positioning of the segment within the broader medical technology market.